Di-Adreson®-F aquosum 25 mg
- Product
Di-Adreson-F aquosum 25 mg, powder for solution for injection
- Authorisation
NL-RVG 00093, SE-MTnr 6097, FI-MTnr 975
- Active ingredient
Prednisolone hemisuccinate sodium 25 mg
- Indication
Acute Lymphatic Leukemia (intrathecal administration) in children and adolescents; Anti-inflammatory; Immunosuppressant effect
- Storage condition
Between 15 – 25 °C
Di-Adreson-F aquosum (DAF) is a medical need product specifically designed for the intrathecal treatment of Acute Lymphatic Leukemia (ALL) in children and adolescents.
DAF does not contain preservatives, complex formers (EDTA) or buffers and can therefore be used safely, also for administration in the head and neck area or intrathecal administration. DAF is administered by injection.
DAF is prescribed to suppress inflammatory responses of various origins and as an immunosuppressive agent.
Legal status
Di-Adreson-F aquosum is a licensed medicine in the Netherlands, Finland (MTnr 975) and Sweden (brandname Precortalon® aquosum, MTnr 06097).
When this medicine is supplied outside these countries, it is considered to be an unlicensed medicine in the country of the recipient.
Availability for (Hospital) Pharmacies
In the Netherlands, DAF is distributed to (hospital)pharmacies by the pharmaceutical wholesalers.
For availability in Finland, please contact pharmaceutical wholesaler Oriola Oy.
In Sweden, Precortalon® aquosum is available via wholesaler Oriola AB.
(Hospital) Pharmacies that would like to know more about the availability of this product outside these countries are welcome to contact us via our contact form.
